Clinical trials: Precise Prognostic and Predictive Signature
Stage I-II Pancreatic Ductal Adenocarcinoma (PDAC), Precise Prognostic and Predictive Signature
Precise Gene Signature for Predicting Outcomes in PDAC
The current TNM staging system is not sufficient for prediction of prognosis and cannot precisely identify the patients who are in greater need of adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT05441189
- Testing
- Resection
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Fourth Affiliated Hospital of Anhui Medical University